Clinical Trials Logo

Drug-drug Interaction clinical trials

View clinical trials related to Drug-drug Interaction.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06066060 Completed - Healthy Clinical Trials

A DDI Study of JMKX000623 and Metformin Hydrochloride

Start date: September 17, 2023
Phase: Phase 1
Study type: Interventional

A phase 1, single center, 1 sequence, 3 period, open label, multiple doses study to evaluate the drug-drug interaction of JMKX000623 tablet and metformin.

NCT ID: NCT06031454 Completed - Clinical trials for Drug Drug Interaction

Drug-durg Interaction of Leritrelvir(RAY1216) With Midazolam, Omeprazole, Rosuvastatin, Verapamil, and Rifampin

Start date: September 1, 2023
Phase: Phase 1
Study type: Interventional

The drug-drug interaction study had been designed to investigate the effect of Leritrelvir on the pharmacokinetics of Midazolam, Omeprazole, Rosuvastatin and the effect of Verapamil and Rifampin on the pharmacokinetics of Leritrelvir

NCT ID: NCT05954624 Completed - Clinical trials for Drug Drug Interaction

Drug-durg Interaction of ZSP1273 With Digoxin, Rosuvastatin,Itraconazole and Probenecid

Start date: July 10, 2023
Phase: Phase 1
Study type: Interventional

The drug-drug interaction study had been designed to investigate the effect of ZSP1273 on the pharmacokinetics of digoxin, Rosuvastatin and the effect of Itraconazole and Probenecid on the pharmacokinetics of ZSP1273

NCT ID: NCT05942365 Completed - Clinical trials for Drug Drug Interaction

A Drug Interaction Study Assess the Effects of ZSP1273 Tablets on the Pharmacokinetics of Warfarin and Midazolam

Start date: June 25, 2023
Phase: Phase 1
Study type: Interventional

This study is a single-center, open label phase I clinical study to characterize the DDIs potential of ZSP1273 With Warfarin and Midazolam in Chinese healthy participants. This study also aims to evaluate the safety and tolerability of ZSP1273 in the presence of Warfarin and Midazolam.

NCT ID: NCT05860114 Completed - Clinical trials for Drug Drug Interaction

Givinostat and Metabolites Pharmacokinetics in Urine and Plasma (Part 3)

Start date: March 21, 2022
Phase: Phase 1
Study type: Interventional

Primary objective: To evaluate the plasma and urine PK of givinostat following multiple oral doses of givinostat. Secondary objective: To assess the safety and tolerability multiple oral doses of givinostat.

NCT ID: NCT05845567 Completed - Clinical trials for Drug Drug Interaction

The Potential of Givinostat as DDI Victim in Co-administration P-gp Inhibitor (Part 2)

Start date: March 21, 2022
Phase: Phase 1
Study type: Interventional

Primary objective: To assess the potential effect of oral Clarithromycin on the single-dose pharmacokinetics of Givinostat. Secondary objective: To assess the safety and tolerability of concomitant administration of Givinostat plus Clarithromycin.

NCT ID: NCT05692570 Completed - Clinical trials for Drug-drug Interaction

A Study of PBI-200 With Ritonavir or Cobicistat in Healthy Volunteers

Start date: September 9, 2022
Phase: Phase 1
Study type: Interventional

This is a drug-drug interaction study in volunteers to evaluate the effect of ritonavir or cobicistat on the pharmacokinetics (PK) of PBI-200.

NCT ID: NCT05658653 Completed - Chronic Disease Clinical Trials

Clinical Utility of CDMT Among VillageMD Providers

Start date: August 16, 2022
Phase: N/A
Study type: Interventional

This is a health system-level research study of physicians and care providers. The purpose of this study is to assess the clinical evaluation and management (drug, procedures, counseling, and other) of a subset of common patient care indications.

NCT ID: NCT05574374 Completed - Clinical trials for Drug Drug Interaction

Drug-drug Interactions Between DWP14012 and DWC202202 in Healthy Subjects

Start date: September 21, 2022
Phase: Phase 1
Study type: Interventional

A randomized, open-label, three-sequence, three-period, multiple dosing crossover, phase 1 clinical trial to evaluate the effect of DWP14012 on the pharmacodynamics of DWC202202 in combination with DWP14012 in healthy subjects

NCT ID: NCT05492318 Completed - Clinical trials for Drug-Drug Interaction

Perpetrator DDI Potential of Givinostat as Inhibitor and Inducer of CYP3A and P-gp Activity

Start date: March 21, 2022
Phase: Phase 1
Study type: Interventional

The study will evaluate the givinostat (ITF2357) potential drug-drug interaction (DDI) at level of CYP3A-mediated metabolism and P-glycoprotein (P-gp) transport.